SpringWorks Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SWTX research report →
About the company
SpringWorks Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative therapies for patient populations grappling with rare diseases and various forms of cancer, often those with significant unmet medical needs. The company's most advanced experimental treatment is nirogacestat, an orally administered small molecule that functions as a gamma secretase inhibitor.
- CEO
- Saqib Islam
- IPO
- 2019
- Employees
- 368
- HQ
- Stamford, CT, US
Price Chart
- Market Cap
- $3.54B
- P/E
- -13.50
- P/S
- 18.48
- P/B
- 7.24
- EV/EBITDA
- -12.67
- Div Yield
- 0.00%
- Gross Margin
- 93.45%
- Op Margin
- -145.17%
- Net Margin
- -134.73%
- ROE
- -46.62%
- ROIC
- -56.88%
- Revenue
- $191.59M · 3417.33%
- Net Income
- $-258,131,000 · 20.60%
- EPS
- $-3.48 · 32.43%
- Op Income
- $-278,131,000
- FCF YoY
- 21.78%
- 52W High
- $62.00
- 52W Low
- $28.21
- 50D MA
- $45.88
- 200D MA
- $41.19
- Beta
- 0.70
- Avg Volume
- 5.85M
Get TickerSpark's AI analysis on SWTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 25 | Edris Badreddin | sell | 33,778 |
| Jul 1, 25 | Edris Badreddin | sell | 3,868 |
| Jul 1, 25 | Edris Badreddin | sell | 149,470 |
| Jul 1, 25 | Edris Badreddin | sell | 100,000 |
| Jul 1, 25 | Edris Badreddin | sell | 240,000 |
| Jul 1, 25 | Edris Badreddin | sell | 169,712 |
| Jul 1, 25 | Edris Badreddin | sell | 120,000 |
| Jul 1, 25 | Edris Badreddin | sell | 78,960 |
| Jul 1, 25 | LYNCH DANIEL | sell | 29,983 |
| Jul 1, 25 | LYNCH DANIEL | sell | 7,464 |
Our SWTX coverage
Recent articles, reports, and earnings notes.
No research on SWTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SWTX report →Similar companies
Peers in the same neighborhood.